Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
119
days
Mapping Two Decades of KRAS-Targeted Drug Development in Cancer: A Bibliometric Analysis of Scientific Evolution and Emerging Therapeutic Trends
Authors
Aly Samy Aly; Zaid Yacoub; Jad YacoubShow moreShow less
Affiliations
1. School of Medicine, Royal College of Surgeons in Ireland, Dublin, IrelandShow moreShow less
133
days
Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots
Authors
Mónica Perea-Vélez; Marie Kirman; Anjana Patel; Mark Pellett; Mandy Tyler-Mahon; Thomas F. Perrone; Cynthia Ban; Susanne Ausborn; Frank MontgomeryShow moreShow less
Affiliations
1. GlaxoSmithKline, Wavre, Belgium; 2. AstraZeneca, Macclesfield, Cheshire, UK; 3. Pfizer Ltd, Surrey, UK; 4. AstraZeneca, Cambridge, UK; 5. GlaxoSmithKline, London, UK; 6. GlaxoSmithKline, Waltham, USA; 7. Sanofi, North York, Canada; 8. Roche, Basel, SwitzerlandShow moreShow less
129
days
Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors
Authors
Ito Furukawa; Mamoru NarukawaShow moreShow less
Affiliations
1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Minato‑ku, Japan; 2. Sanofi Specialty Care Medical, Tokyo, JapanShow moreShow less
166
days
Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan
Authors
Shingo Yamaguchi; Eiji Nakatani; Ryuta AsadaShow moreShow less
Affiliations
1. Department of Medical Research and Development Strategy, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 2. Laboratory of Biostatistics, NHO Nagoya Medical Center, Nagoya, JapanShow moreShow less
213
days
The Role of Digital Twins in Clinical Trials: A New Perspective on Methodological and Statistical Challenges
Authors
Fatma Nur CicinShow moreShow less
Affiliations
1. Department of Management Information Systems, Faculty of Economics, Administrative and Social Sciences, Istinye University, Istanbul, TürkiyeShow moreShow less
74
days
Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA)
Authors
Paul Marvin Quizon; Patriz Miga Lintag-Raymundo; Wan Lee Chow; Serene Huang; Thanh Tu Nguyen; R. Iin Nurhayati; Wipada Rodtanaporn; Tse Siang KangShow moreShow less
Affiliations
1. Pfizer, Inc, Makati City, Philippines; 2. Pfizer (Malaysia) Sdn. Bhd, Kuala Lumpur, Malaysia; 3. Pfizer Pte. Ltd, Singapore, Singapore; 4. Pfizer (Vietnam) Ltd. Co, Hanoi, Vietnam; 5. PT Pfizer Indonesia, Jakarta, Indonesia; 6. Pfizer (Thailand) Ltd, Bangkok, ThailandShow moreShow less
FAQ
How long does Therapeutic Innovation & Regulatory Science take to review a manuscript?
As of 2026-11-19, CrushSCI has 21 complete review records for Therapeutic Innovation & Regulatory Science. The fastest paper went from submission to acceptance in 44 days (Identifying and Deploying Benchmarks for Clinical Research at Sites, received 2026-02-04, accepted 2026-03-20); the slowest took 303 days. The average is 159.5 days and the median is 156 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
